Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Interest Expenses (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Interest Expenses for 4 consecutive years, with $12000.0 as the latest value for Q4 2025.

  • Quarterly Interest Expenses fell 45.45% to $12000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $63000.0 through Dec 2025, down 38.24% year-over-year, with the annual reading at $63000.0 for FY2025, 38.24% down from the prior year.
  • Interest Expenses hit $12000.0 in Q4 2025 for Taysha Gene Therapies, down from $15000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $1.5 million in Q3 2023 to a low of $8000.0 in Q1 2022.
  • Historically, Interest Expenses has averaged $518562.5 across 4 years, with a median of $28000.0 in 2024.
  • Biggest five-year swings in Interest Expenses: soared 17075.0% in 2023 and later crashed 98.37% in 2024.
  • Year by year, Interest Expenses stood at $1.3 million in 2022, then crashed by 45.36% to $713000.0 in 2023, then plummeted by 96.91% to $22000.0 in 2024, then crashed by 45.45% to $12000.0 in 2025.
  • Business Quant data shows Interest Expenses for TSHA at $12000.0 in Q4 2025, $15000.0 in Q3 2025, and $17000.0 in Q2 2025.